ClinicalTrials.gg

Program

COM-701

Also written as “COM701”, “Evaluation of safety/tolerability: COM902 in combination with COM701 (both at the RDFE)” and “Cohort expansion: COM902 in combination with COM701 (both at the RDFE).”.

Its studies are mostly in Ovarian Neoplasms, led by Compugen.

Furthest: phase 2, since Mar 12, 20253 company-led studies, 1 open or runningNext primary completion: Mar 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Compugen31 open or runningphase 2since Mar 12, 2025Sep 10, 2018Mar 2027phase 2 · NCT06888921

Also a collaborator on its studies: Bristol-Myers Squibb.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 10, 2018First study: phase 1 study in Ovarian NeoplasmsFirst studyNCT03667716 · 121 enrolled · United States
  2. Apr 15, 2020Phase 1 study in Ovarian NeoplasmsNCT04354246 · 94 enrolled · United States
  3. Mar 12, 2025Phase 2 study in Ovarian NeoplasmsNCT06888921 · 60 enrolled · United States, France, Israel

Ahead

  1. Mar 2027Primary completion: phase 2 study in Ovarian NeoplasmsNCT06888921

TargetBeta

PVRIG →read by rule
“A humanized, hybridoma monoclonal antibody against the poliovirus receptor-related immunoglobulin (PVRIG; PVR Related Immunoglobulin Domain Containing Protein; CD112R), ”NCIt, by rule

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06888921Ovarian Neoplasms · United States, France, Israel2Active, not recruitingMar 202760
NCT04354246Ovarian Neoplasms · United States1CompletedApr 1, 202694
NCT03667716Ovarian Neoplasms · United States1CompletedJan 30, 2024121

How it is read

Names in the registry

  • “COM701”, 2 entries
  • “Evaluation of safety/tolerability: COM902 in combination with COM701 (both at the RDFE)”, 1 entry
  • “Cohort expansion: COM902 in combination with COM701 (both at the RDFE).”, 1 entry

Codes read as this program: COM701.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.